California Stem Cell, Inc. Submits Phase II Clinical Trial Protocol To FDA For Treating Ovarian Cancer
1/23/2014 9:11:31 AM
IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (“CSC”) announced today it has submitted a Phase II protocol to the U.S. Food and Drug Administration for a randomized, double-blind study to evaluate CSC’s patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by